When was Zhaoke Ophthalmology founded?

Zhaoke Ophthalmology was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Zhaoke Ophthalmology located?

Zhaoke Ophthalmology is headquartered in Hong Kong, China.

Who is the current CEO of Zhaoke Ophthalmology?

Li Xiaoyi of Zhaoke Ophthalmology.

How many employees does Zhaoke Ophthalmology have?

As of Jul 31, 2026, the latest employee count at Zhaoke Ophthalmology is 18.

Is Zhaoke Ophthalmology a funded company?

Zhaoke Ophthalmology is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Oct 09, 2020.

When was the latest funding round of Zhaoke Ophthalmology?

Zhaoke Ophthalmology's latest funding was a $***** Series B round on Oct 09, 2020, with participation from 3 investors.

Where does Zhaoke Ophthalmology rank among its competitors?

Zhaoke Ophthalmology ranks 729th amongst 2655 active competitors, of which 904 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Zhaoke Ophthalmology?

Zhaoke Ophthalmology's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Zhaoke Ophthalmology - 2026 Company Profile, Team, Funding & Competitors

Zhaoke Ophthalmology is a public company based in Hong Kong (China), founded in 2017. It operates as a Developer of therapeutics for ophthalmic diseases. Zhaoke Ophthalmology has raised an undisclosed amount in funding from investors like TPG, Loayal Valley Capital and Hillhouse. The company has 2655 active competitors, including 904 funded and 678 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutics for ophthalmic diseases. The drugs include RGN-259 and cyclosporine gel for dry eye, bevacizumab-based antibody and PAN-90806 for wet age-related macular degeneration, ZK002 for diabetic macular edema, atropine for myopia, and generic drugs for glaucoma.

Website: www.zkoph.com
Email ID: *****@zkoph.com
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Hong Kong, China

Stage

Public

Latest Funding Round

Series B, Oct 09, 2020, $*****

Investors

TPG & 4 more

Ranked

729^th among 2655 active competitors

Employee Count

18 as on Jul 31, 2026

Similar Companies

Viridian Therapeutics & 289 more

Exit Details

Public

View Zhaoke Ophthalmology's full profile

Zhaoke Ophthalmology got listed on Apr 29, 2021.

Click here to take a look at Zhaoke Ophthalmology's IPO in detail

Zhaoke Ophthalmology has raised funding over 1 round. Its latest funding round was a Series B round on Oct 09, 2020 for $*****. 3 investors participated in its latest round. Zhaoke Ophthalmology has 5 institutional investors.

Here is the list of recent funding rounds of Zhaoke Ophthalmology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 09, 2020	4549028	Series B	2680725	7146907	1653010	6515923

Access funding benchmarks and valuations. Sign up today!

View details of Zhaoke Ophthalmology's funding rounds and investors

Zhaoke Ophthalmology's employee count trend

Zhaoke Ophthalmology has 18 employees as of Jul 26. Here is Zhaoke Ophthalmology's employee count trend over the years:

Employee count trend for Zhaoke Ophthalmology

Uncover Zhaoke Ophthalmology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zhaoke Ophthalmology include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Zhaoke Ophthalmology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
729th	Zhaoke Ophthalmology 2017, Hong Kong (China), Public	Developer of therapeutics for ophthalmic diseases	-	Greater Bay Area Homeland Investments, Loayal Valley Capital ... & 3 others	42/100